1
|
Cuenca-Bermejo L, Fernández-Del Palacio MJ, de Cassia Gonçalves V, Bautista-Hernández V, Sánchez-Rodrigo C, Fernández-Villalba E, Kublickiene K, Raparelli V, Kautzky-Willer A, Norris CM, Pilote L, Herrero MT. Age and Sex Determine Electrocardiogram Parameters in the Octodon degus. Biology (Basel) 2023; 12:747. [PMID: 37237559 PMCID: PMC10215068 DOI: 10.3390/biology12050747] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/17/2023] [Revised: 05/02/2023] [Accepted: 05/12/2023] [Indexed: 05/28/2023]
Abstract
Cardiovascular diseases represent the leading cause of mortality and morbidity worldwide, and age is an important risk factor. Preclinical models provide supportive evidence toward age-related cardiac changes, as well as allow for the study of pathological aspects of the disease. In the present work, we evaluated the electrocardiogram (ECG) recording in the O. degus during the aging process in both females and males. Taking into account the age and sex, our study provides the normal ranges for the heart rate, duration and voltage of the ECG waves and intervals, as well as electrical axis deviation. We found that the QRS complex duration and QTc significantly increased with age, whereas the heart rate significantly decreased. On the other hand, the P wave, PR and QTc segments durations, S wave voltage and electrical axis were found to be significantly different between males and females. The heart rhythm was also altered in aged animals, resulting in an increased incidence of arrhythmias, especially in males. Based on these results, we suggest that this rodent model could be useful for cardiovascular research, including impacts of aging and biological sex.
Collapse
Affiliation(s)
- Lorena Cuenca-Bermejo
- Clinical & Experimental Neuroscience (NiCE), Biomedical Research Institute of Murcia (IMIB-Pascual Parrilla), University of Murcia, 30120 Murcia, Spain; (L.C.-B.); (V.d.C.G.); (C.S.-R.); (E.F.-V.)
- Institute for Aging Research (IUIE), Campus Mare Nostrum, European University for Wellbeing (EUniWell), 30100 Murcia, Spain
| | | | - Valeria de Cassia Gonçalves
- Clinical & Experimental Neuroscience (NiCE), Biomedical Research Institute of Murcia (IMIB-Pascual Parrilla), University of Murcia, 30120 Murcia, Spain; (L.C.-B.); (V.d.C.G.); (C.S.-R.); (E.F.-V.)
- Disciplina de Neurociência, Departamento de Neurologia e Neurocirurgia, Universidade Federal de São Paulo (UNIFESP), São Paulo 04039-032, Brazil
| | | | - Consuelo Sánchez-Rodrigo
- Clinical & Experimental Neuroscience (NiCE), Biomedical Research Institute of Murcia (IMIB-Pascual Parrilla), University of Murcia, 30120 Murcia, Spain; (L.C.-B.); (V.d.C.G.); (C.S.-R.); (E.F.-V.)
- Institute for Aging Research (IUIE), Campus Mare Nostrum, European University for Wellbeing (EUniWell), 30100 Murcia, Spain
| | - Emiliano Fernández-Villalba
- Clinical & Experimental Neuroscience (NiCE), Biomedical Research Institute of Murcia (IMIB-Pascual Parrilla), University of Murcia, 30120 Murcia, Spain; (L.C.-B.); (V.d.C.G.); (C.S.-R.); (E.F.-V.)
- Institute for Aging Research (IUIE), Campus Mare Nostrum, European University for Wellbeing (EUniWell), 30100 Murcia, Spain
| | - Karolina Kublickiene
- Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, 17177 Stockholm, Sweden;
| | - Valeria Raparelli
- Department of Translational Medicine, University of Ferrara, 44124 Ferrara, Italy;
- University Center for Studies on Gender Medicine, University of Ferrara, 44121 Ferrara, Italy
| | - Alexandra Kautzky-Willer
- Division of Endocrinology and Metabolism, Department of Medicine III, Medical University of Vienna, 1090 Vienna, Austria;
| | - Colleen M. Norris
- Faculty of Nursing, University of Alberta, Edmonton, AB T6G 2R3, Canada;
- Cardiovascular and Stroke Strategic Clinical Network, Alberta Health Services, Edmonton, AB T5J 3E4, Canada
| | - Louise Pilote
- Division of Clinical Epidemiology, Research Institute of McGill University Health Centre, McGill University, Montreal, QC H4A 3J1, Canada;
| | - María Trinidad Herrero
- Clinical & Experimental Neuroscience (NiCE), Biomedical Research Institute of Murcia (IMIB-Pascual Parrilla), University of Murcia, 30120 Murcia, Spain; (L.C.-B.); (V.d.C.G.); (C.S.-R.); (E.F.-V.)
- Institute for Aging Research (IUIE), Campus Mare Nostrum, European University for Wellbeing (EUniWell), 30100 Murcia, Spain
| |
Collapse
|
2
|
Cuenca-Bermejo L, Prinetti A, Kublickiene K, Raparelli V, Kautzky-Willer A, Norris CM, Pilote L, Herrero MT. Fundamental Neurochemistry Review: Old brain stories- Influence of age and sex on the neurodegeneration-associated lipid changes. J Neurochem 2023. [PMID: 37161795 DOI: 10.1111/jnc.15834] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2022] [Revised: 03/30/2023] [Accepted: 04/19/2023] [Indexed: 05/11/2023]
Abstract
Brain aging is a naturally occurring process resulting in the decline of cognitive functions and increased vulnerability to develop age-associated disorders. Fluctuation in lipid species is crucial for normal brain development and function. However, impaired lipid metabolism and changes in lipid composition in the brain have been increasingly recognized to play a crucial role in physiological aging, as well as in several neurodegenerative diseases. In the last decades, the role of sexual dimorphism in the vulnerability to develop age-related neurodegeneration has increased. However, further studies are warranted for detailed assessment to how age, sex and additional non biological factors may influence the lipid changes in brains. The aim of this work is to address the presence of sex differences in the brain lipid changes that occur along aging, and in the two most common age-related neurodegenerative disorders (Alzheimer's and Parkinson's disease). We included the studies that assessed lipid-related alterations in the brain of both humans and experimental models. Additionally, we explored the influence of sex on lipid-lowering therapies. We conclude that sex exerts a notable effect on lipid modifications occurring with age and neurodegeneration, and in the lipid-reducing interventions. Therefore, the application of sex as experimental variable is strongly encouraged for future research in the field towards precision medicine approach.
Collapse
Affiliation(s)
- Lorena Cuenca-Bermejo
- Clinical & Experimental Neuroscience (NiCE), Biomedical Research Institute of Murcia (IMIB- Pascual Parrilla), Institute for Ageing Research (IUIE- EUniWel), University of Murcia, Spain
- Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy
| | - Alessandro Prinetti
- Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy
| | - Karolina Kublickiene
- Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
| | - Valeria Raparelli
- Department of Translational Medicine, University of Ferrara, Ferrara, Italy and University Center for Studies on Gender Medicine, University of Ferrara, Ferrara, Italy
| | - Alexandra Kautzky-Willer
- Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
| | - Colleen M Norris
- Faculty of Nursing, University of Alberta, Edmonton, AB, Canada & Cardiovascular and Stroke Strategic Clinical Network, Alberta Health Services, Edmonton, AB, Canada
| | - Louise Pilote
- Division of Clinical Epidemiology, Research Institute of McGill University Health Centre, QC, Canada
| | - M T Herrero
- Clinical & Experimental Neuroscience (NiCE), Biomedical Research Institute of Murcia (IMIB- Pascual Parrilla), Institute for Ageing Research (IUIE- EUniWel), University of Murcia, Spain
| |
Collapse
|
3
|
Herrero MT, Yuste JE, Cuenca-Bermejo L, Almela P, Arenas-Betancur L, De Pablos V, Gonzalez-Cuello A, Del Bel E, Navarro-Zaragoza J, Fernández-Villalba E. 7-Nitroindazole reduces L-DOPA-induced dyskinesias in non-human Parkinsonian primate. Open Biol 2023; 13:220370. [PMID: 37192671 DOI: 10.1098/rsob.220370] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Accepted: 03/31/2023] [Indexed: 05/18/2023] Open
Abstract
Nitric oxide (NO) plays a pivotal role in integrating dopamine transmission in the basal ganglia and has been implicated in the pathogenesis of Parkinson disease (PD). The objective of this study was to ascertain whether the NO synthase inhibitor, 7-nitroindazole (7-NI), is able to reduce L-DOPA-induced dyskinesias (LIDs) in a non-human primate model of PD chronically intoxicated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Six Parkinsonian macaques were treated daily with L-DOPA for 3-4 months until they developed LIDs. Three animals were then co-treated with a single dose of 7-NI administered 45 min before each L-DOPA treatment. Dyskinetic MPTP-treated monkeys showed a significant decrease in LIDs compared with their scores without 7-NI treatment (p < 0.05). The anti-Parkinsonian effect of L-DOPA was similar in all three monkeys with and without 7-NI co-treatment. This improvement was significant with respect to the intensity and duration of LIDs while the beneficial effect of L-DOPA treatment was maintained and could represent a promising therapy to improve the quality of life of PD patients.
Collapse
Affiliation(s)
- M T Herrero
- Clinical and Experimental Neuroscience (NiCE), Institute for Aging Research, School of Medicine, Campus Mare Nostrum, The European University for Well-Being, EUniWell, University of Murcia, Spain
- Biomedical Research Institute of Murcia (IMIB-Pascual Parrilla), Campus of Health Sciences, University of Murcia, 30120 Murcia, Spain
| | - J E Yuste
- Clinical and Experimental Neuroscience (NiCE), Institute for Aging Research, School of Medicine, Campus Mare Nostrum, The European University for Well-Being, EUniWell, University of Murcia, Spain
| | - L Cuenca-Bermejo
- Clinical and Experimental Neuroscience (NiCE), Institute for Aging Research, School of Medicine, Campus Mare Nostrum, The European University for Well-Being, EUniWell, University of Murcia, Spain
- Biomedical Research Institute of Murcia (IMIB-Pascual Parrilla), Campus of Health Sciences, University of Murcia, 30120 Murcia, Spain
| | - P Almela
- Department of Pharmacology, School of Medicine, University of Murcia, Campus Mare Nostrum, 30100 Murcia, Spain
- Biomedical Research Institute of Murcia (IMIB-Pascual Parrilla), Campus of Health Sciences, University of Murcia, 30120 Murcia, Spain
| | - L Arenas-Betancur
- Clinical and Experimental Neuroscience (NiCE), Institute for Aging Research, School of Medicine, Campus Mare Nostrum, The European University for Well-Being, EUniWell, University of Murcia, Spain
| | - V De Pablos
- Clinical and Experimental Neuroscience (NiCE), Institute for Aging Research, School of Medicine, Campus Mare Nostrum, The European University for Well-Being, EUniWell, University of Murcia, Spain
- Biomedical Research Institute of Murcia (IMIB-Pascual Parrilla), Campus of Health Sciences, University of Murcia, 30120 Murcia, Spain
| | - A Gonzalez-Cuello
- Clinical and Experimental Neuroscience (NiCE), Institute for Aging Research, School of Medicine, Campus Mare Nostrum, The European University for Well-Being, EUniWell, University of Murcia, Spain
- Biomedical Research Institute of Murcia (IMIB-Pascual Parrilla), Campus of Health Sciences, University of Murcia, 30120 Murcia, Spain
| | - E Del Bel
- Department of Basic and Oral Biology, Faculty of Odontology of Ribeirão Preto (FORP-USP) and Center for Research Support on Applied Neuroscience (NAPNA-USP), University of São Paulo, Ribeirão Preto, SP 14040-904, Brazil
| | - J Navarro-Zaragoza
- Department of Pharmacology, School of Medicine, University of Murcia, Campus Mare Nostrum, 30100 Murcia, Spain
- Biomedical Research Institute of Murcia (IMIB-Pascual Parrilla), Campus of Health Sciences, University of Murcia, 30120 Murcia, Spain
| | - E Fernández-Villalba
- Clinical and Experimental Neuroscience (NiCE), Institute for Aging Research, School of Medicine, Campus Mare Nostrum, The European University for Well-Being, EUniWell, University of Murcia, Spain
- Biomedical Research Institute of Murcia (IMIB-Pascual Parrilla), Campus of Health Sciences, University of Murcia, 30120 Murcia, Spain
| |
Collapse
|
4
|
De Araújo FM, Frota AF, de Jesus LB, Cuenca-Bermejo L, Ferreira KMS, Santos CC, Soares EN, Souza JT, Sanches FS, Costa ACS, Farias AA, de Fatima Dias Costa M, Munoz P, Menezes-Filho JA, Segura-Aguilar J, Costa SL, Herrero MT, Silva VDA. Protective Effects of Flavonoid Rutin Against Aminochrome Neurotoxicity. Neurotox Res 2023; 41:224-241. [PMID: 36723781 DOI: 10.1007/s12640-022-00616-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2022] [Revised: 11/17/2022] [Accepted: 12/02/2022] [Indexed: 02/02/2023]
Abstract
Causes of dopaminergic neuronal loss in Parkinson's disease (PD) are subject of investigation and the common use of models of acute neurodegeneration induced by neurotoxins 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 6-hydroxydopamine, and rotenone contributed to advances in the study of PD. However, the use of study models more similar to the pathophysiology of PD is required for advances in early diagnosis and translational pharmacology. Aminochrome (AMI), a compound derived from dopamine oxidation and a precursor of neuromelanin, is able to induce all the mechanisms associated with neurodegeneration. Previously, we showed AMI is cytotoxic in primary culture of mesencephalic cells (PCMC) and induces in vitro and in vivo neuroinflammation. On the other hand, the effect of rutin in central nervous system cells has revealed anti-inflammatory, antioxidative, and neuroprotective potential. However, there have been no data studies on the effect of rutin against aminochrome neurotoxicity. Here, we show that rutin prevents lysosomal dysfunction and aminochrome-induced cell death in SHSY-5Y cells, protects PCMC against aminochrome cytotoxicity, and prevents in vivo loss of dopaminergic neurons in substantia nigra pars compacta (SNPc), as well as microgliosis and astrogliosis. Additionally, we show that rutin decreases levels of interleukin-1β (IL-1β) mRNA and increases levels of glia-derived neurotrophic factor (GDNF) and nerve-derived neurotrophic factor (NGF) mRNA. We evidence for the first time the protective effect of rutin on PD aminochrome-induced models and suggest the potential role of the anti-inflammatory activity and upregulation of NGF and GDNF in the mechanism of rutin action against aminochrome neurotoxicity.
Collapse
Affiliation(s)
- Fillipe Mendes De Araújo
- Laboratory of Neurochemistry and Cell Biology, Department of Biochemistry and Biophysics, Institute of Health Sciences, Federal University of Bahia, Salvador, Brazil
- Clinical & Experimental Neuroscience (NiCE). Institute for Bio-Health Research of Murcia (IMIB), Institute for Aging Research (IUIE), School of Medicine, Campus Mare Nostrum, University of Murcia, Murcia, Spain
| | - Annyta F Frota
- Laboratory of Neurochemistry and Cell Biology, Department of Biochemistry and Biophysics, Institute of Health Sciences, Federal University of Bahia, Salvador, Brazil
| | - Lívia B de Jesus
- Laboratory of Neurochemistry and Cell Biology, Department of Biochemistry and Biophysics, Institute of Health Sciences, Federal University of Bahia, Salvador, Brazil
| | - Lorena Cuenca-Bermejo
- Clinical & Experimental Neuroscience (NiCE). Institute for Bio-Health Research of Murcia (IMIB), Institute for Aging Research (IUIE), School of Medicine, Campus Mare Nostrum, University of Murcia, Murcia, Spain
| | - Kariny Maria S Ferreira
- Laboratory of Neurochemistry and Cell Biology, Department of Biochemistry and Biophysics, Institute of Health Sciences, Federal University of Bahia, Salvador, Brazil
| | - Cleonice Creusa Santos
- Laboratory of Neurochemistry and Cell Biology, Department of Biochemistry and Biophysics, Institute of Health Sciences, Federal University of Bahia, Salvador, Brazil
| | - Erica N Soares
- Laboratory of Neurochemistry and Cell Biology, Department of Biochemistry and Biophysics, Institute of Health Sciences, Federal University of Bahia, Salvador, Brazil
| | - Jéssica T Souza
- Laboratory of Neurochemistry and Cell Biology, Department of Biochemistry and Biophysics, Institute of Health Sciences, Federal University of Bahia, Salvador, Brazil
| | - Flávia S Sanches
- Laboratory of Neurochemistry and Cell Biology, Department of Biochemistry and Biophysics, Institute of Health Sciences, Federal University of Bahia, Salvador, Brazil
| | - Ana Carla S Costa
- Laboratory of Neurochemistry and Cell Biology, Department of Biochemistry and Biophysics, Institute of Health Sciences, Federal University of Bahia, Salvador, Brazil
| | - Alana A Farias
- Laboratory of Neurochemistry and Cell Biology, Department of Biochemistry and Biophysics, Institute of Health Sciences, Federal University of Bahia, Salvador, Brazil
| | - Maria de Fatima Dias Costa
- Laboratory of Neurochemistry and Cell Biology, Department of Biochemistry and Biophysics, Institute of Health Sciences, Federal University of Bahia, Salvador, Brazil
| | - Patrícia Munoz
- Instituto de Ciencias Biomedicas, Faculdad de Ciencias de la Salud, Universidad Autónoma de Chile, Santiago, Chile
- Molecular & Clinical Pharmacology, ICBM, Faculty of Medicine, University of Chile, Independencia, 1027, Santiago, Chile
| | - José A Menezes-Filho
- Graduate Program in Pharmacy, College of Pharmacy, Federal University of Bahia, Salvador, Brazil
| | - Juan Segura-Aguilar
- Molecular & Clinical Pharmacology, ICBM, Faculty of Medicine, University of Chile, Independencia, 1027, Santiago, Chile
| | - Silvia Lima Costa
- Laboratory of Neurochemistry and Cell Biology, Department of Biochemistry and Biophysics, Institute of Health Sciences, Federal University of Bahia, Salvador, Brazil
| | - Maria Trinidad Herrero
- Clinical & Experimental Neuroscience (NiCE). Institute for Bio-Health Research of Murcia (IMIB), Institute for Aging Research (IUIE), School of Medicine, Campus Mare Nostrum, University of Murcia, Murcia, Spain.
| | - Victor Diogenes Amaral Silva
- Laboratory of Neurochemistry and Cell Biology, Department of Biochemistry and Biophysics, Institute of Health Sciences, Federal University of Bahia, Salvador, Brazil.
| |
Collapse
|
5
|
Romo-Vaquero M, Fernández-Villalba E, Gil-Martinez AL, Cuenca-Bermejo L, Espín JC, Herrero MT, Selma MV. Urolithins: potential biomarkers of gut dysbiosis and disease stage in Parkinson's patients. Food Funct 2022; 13:6306-6316. [PMID: 35611932 DOI: 10.1039/d2fo00552b] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Gut microbiota alteration (gut dysbiosis) occurs during the onset and progression of Parkinson's disease. Gut dysbiosis biomarkers could be relevant to prodromal disease. Urolithins, anti-inflammatory metabolites produced from some dietary polyphenols by specific gut microbial ecologies (urolithin metabotypes), have been proposed as biomarkers of gut microbiota composition and functionality. However, this has not been explored in Parkinson's disease patients. The current study aimed to assess associations between urolithin metabotypes, gut dysbiosis and disease severity in Parkinson's disease patients. Participants (52 patients and 117 healthy controls) provided stool samples for microbiota sequencing and urine samples for urolithin profiling before and after consuming 30 g of walnuts for three days. Data on demographics, medication, disease duration and Hoehn and Yahr disease stage were collected. We observed a significant gradual increase of urolithin non-producers (metabotype-0) as the disease severity increased. The gut microbiome of metabotype-0 patients and patients with the greatest severity was characterized by a more altered bacterial composition, i.e., increased pro-inflammatory Enterobacteriaceae and reduced protective bacteria against autoimmune and inflammatory processes, including butyrate and urolithin-producing bacteria (Lachnospiraceae members and Gordonibacter). Besides, their microbiome was characterized by predictive functions of lipopolysaccharide biosynthesis and metabolism of glutathione, cysteine and methionine that could indirectly reflect the gut pro-inflammatory status. Urolithin detection in urine is a feasible, non-invasive and fast approach that can reflect gut microbiome dysbiosis and intestinal inflammation in Parkinson's disease patients. Our current study could provide novel strategies for improving diagnostics, and for preventing and treating disease progression in microbiota-based interventions.
Collapse
Affiliation(s)
- María Romo-Vaquero
- Laboratory of Food & Health, Research Group on Quality, Safety and Bioactivity of Plant Foods, CEBAS-CSIC, Campus de Espinardo, Murcia 30100, Spain.
| | - Emiliano Fernández-Villalba
- Institute of Biomedical Research of Murcia (IMIB), Campus de Ciencias de la Salud, Carretera Buenavista s/n, El Palmar, Murcia 30120, Spain.,Clinical & Experimental Neuroscience, Institute for Aging Research, School of Medicine, University of Murcia, Murcia, Spain.
| | - Ana-Luisa Gil-Martinez
- Institute of Biomedical Research of Murcia (IMIB), Campus de Ciencias de la Salud, Carretera Buenavista s/n, El Palmar, Murcia 30120, Spain.,Clinical & Experimental Neuroscience, Institute for Aging Research, School of Medicine, University of Murcia, Murcia, Spain.
| | - Lorena Cuenca-Bermejo
- Institute of Biomedical Research of Murcia (IMIB), Campus de Ciencias de la Salud, Carretera Buenavista s/n, El Palmar, Murcia 30120, Spain.,Clinical & Experimental Neuroscience, Institute for Aging Research, School of Medicine, University of Murcia, Murcia, Spain.
| | - Juan Carlos Espín
- Laboratory of Food & Health, Research Group on Quality, Safety and Bioactivity of Plant Foods, CEBAS-CSIC, Campus de Espinardo, Murcia 30100, Spain.
| | - María Trinidad Herrero
- Institute of Biomedical Research of Murcia (IMIB), Campus de Ciencias de la Salud, Carretera Buenavista s/n, El Palmar, Murcia 30120, Spain.,Clinical & Experimental Neuroscience, Institute for Aging Research, School of Medicine, University of Murcia, Murcia, Spain.
| | - María Victoria Selma
- Laboratory of Food & Health, Research Group on Quality, Safety and Bioactivity of Plant Foods, CEBAS-CSIC, Campus de Espinardo, Murcia 30100, Spain.
| |
Collapse
|
6
|
Cuenca-Bermejo L, Almela P, Navarro-Zaragoza J, Fernández Villalba E, González-Cuello AM, Laorden ML, Herrero MT. Cardiac Changes in Parkinson's Disease: Lessons from Clinical and Experimental Evidence. Int J Mol Sci 2021; 22:13488. [PMID: 34948285 PMCID: PMC8705692 DOI: 10.3390/ijms222413488] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2021] [Revised: 12/10/2021] [Accepted: 12/11/2021] [Indexed: 01/18/2023] Open
Abstract
Dysautonomia is a common non-motor symptom in Parkinson's disease (PD). Most dysautonomic symptoms appear due to alterations in the peripheral nerves of the autonomic nervous system, including both the sympathetic and parasympathetic nervous systems. The degeneration of sympathetic nerve fibers and neurons leads to cardiovascular dysfunction, which is highly prevalent in PD patients. Cardiac alterations such as orthostatic hypotension, heart rate variability, modifications in cardiogram parameters and baroreflex dysfunction can appear in both the early and late stages of PD, worsening as the disease progresses. In PD patients it is generally found that parasympathetic activity is decreased, while sympathetic activity is increased. This situation gives rise to an imbalance of both tonicities which might, in turn, promote a higher risk of cardiac damage through tachycardia and vasoconstriction. Cardiovascular abnormalities can also appear as a side effect of PD treatment: L-DOPA can decrease blood pressure and aggravate orthostatic hypotension as a result of a negative inotropic effect on the heart. This unwanted side effect limits the therapeutic use of L-DOPA in geriatric patients with PD and can contribute to the number of hospital admissions. Therefore, it is essential to define the cardiac features related to PD for the monitorization of the heart condition in parkinsonian individuals. This information can allow the application of intervention strategies to improve the course of the disease and the proposition of new alternatives for its treatment to eliminate or reverse the motor and non-motor symptoms, especially in geriatric patients.
Collapse
Affiliation(s)
- Lorena Cuenca-Bermejo
- Clinical and Experimental Neuroscience Group/Biomedical Research Institute of Murcia (NiCE-IMIB)/Institute for Aging Research, School of Medicine, University of Murcia, 30100 Murcia, Spain; (L.C.-B.); (A.-M.G.-C.)
| | - Pilar Almela
- Department of Pharmacology, School of Medicine, Biomedical Research Institute of Murcia (IMIB), University of Murcia, 30100 Murcia, Spain; (P.A.); (J.N.-Z.); (M.-L.L.)
| | - Javier Navarro-Zaragoza
- Department of Pharmacology, School of Medicine, Biomedical Research Institute of Murcia (IMIB), University of Murcia, 30100 Murcia, Spain; (P.A.); (J.N.-Z.); (M.-L.L.)
| | - Emiliano Fernández Villalba
- Clinical and Experimental Neuroscience Group/Biomedical Research Institute of Murcia (NiCE-IMIB)/Institute for Aging Research, School of Medicine, University of Murcia, 30100 Murcia, Spain; (L.C.-B.); (A.-M.G.-C.)
| | - Ana-María González-Cuello
- Clinical and Experimental Neuroscience Group/Biomedical Research Institute of Murcia (NiCE-IMIB)/Institute for Aging Research, School of Medicine, University of Murcia, 30100 Murcia, Spain; (L.C.-B.); (A.-M.G.-C.)
| | - María-Luisa Laorden
- Department of Pharmacology, School of Medicine, Biomedical Research Institute of Murcia (IMIB), University of Murcia, 30100 Murcia, Spain; (P.A.); (J.N.-Z.); (M.-L.L.)
| | - María-Trinidad Herrero
- Clinical and Experimental Neuroscience Group/Biomedical Research Institute of Murcia (NiCE-IMIB)/Institute for Aging Research, School of Medicine, University of Murcia, 30100 Murcia, Spain; (L.C.-B.); (A.-M.G.-C.)
| |
Collapse
|
7
|
Cuenca-Bermejo L, Almela P, Gallo-Soljancic P, Yuste JE, de Pablos V, Bautista-Hernández V, Fernández-Villalba E, Laorden ML, Herrero MT. Cardiac tyrosine hydroxylase activation and MB-COMT in dyskinetic monkeys. Sci Rep 2021; 11:19871. [PMID: 34615910 PMCID: PMC8494805 DOI: 10.1038/s41598-021-99237-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2020] [Accepted: 09/21/2021] [Indexed: 11/30/2022] Open
Abstract
The impact of age-associated disorders is increasing as the life expectancy of the population increments. Cardiovascular diseases and neurodegenerative disorders, such as Parkinson’s disease, have the highest social and economic burden and increasing evidence show interrelations between them. Particularly, dysfunction of the cardiovascular nervous system is part of the dysautonomic symptoms of Parkinson’s disease, although more studies are needed to elucidate the role of cardiac function on it. We analyzed the dopaminergic system in the nigrostriatal pathway of Parkinsonian and dyskinetic monkeys and the expression of some key proteins in the metabolism and synthesis of catecholamines in the heart: total and phosphorylated (phospho) tyrosine hydroxylase (TH), and membrane (MB) and soluble (S) isoforms of catechol-O-methyl transferase (COMT). The dopaminergic system was significantly depleted in all MPTP-intoxicated monkeys. MPTP- and MPTP + L-DOPA-treated animals also showed a decrease in total TH expression in both right (RV) and left ventricle (LV). We found a significant increase of phospho-TH in both groups (MPTP and MPTP + L-DOPA) in the LV, while this increase was only observed in MPTP-treated monkeys in the RV. MB-COMT analysis showed a very significant increase of this isoform in the LV of MPTP- and MPTP + L-DOPA-treated animals, with no significant differences in S-COMT levels. These data suggest that MB-COMT is the main isoform implicated in the cardiac noradrenergic changes observed after MPTP treatment, suggesting an increase in noradrenaline (NA) metabolism. Moreover, the increase of TH activity indicates that cardiac noradrenergic neurons still respond despite MPTP treatment.
Collapse
Affiliation(s)
- Lorena Cuenca-Bermejo
- Clinical & Experimental Neuroscience (NICE), Institute for Bio-Health Research of Murcia (IMIB), Institute for Aging Research (IUIE), School of Medicine, Campus Mare Nostrum, University of Murcia, 30100, Murcia, Spain
| | - Pilar Almela
- Department of Pharmacology, School of Medicine, Campus Mare Nostrum, University of Murcia, Institute for Bio-Health Research of Murcia (IMIB), 30100, Murcia, Spain.
| | - Pablo Gallo-Soljancic
- Clinical & Experimental Neuroscience (NICE), Institute for Bio-Health Research of Murcia (IMIB), Institute for Aging Research (IUIE), School of Medicine, Campus Mare Nostrum, University of Murcia, 30100, Murcia, Spain
| | - José E Yuste
- Clinical & Experimental Neuroscience (NICE), Institute for Bio-Health Research of Murcia (IMIB), Institute for Aging Research (IUIE), School of Medicine, Campus Mare Nostrum, University of Murcia, 30100, Murcia, Spain
| | - Vicente de Pablos
- Clinical & Experimental Neuroscience (NICE), Institute for Bio-Health Research of Murcia (IMIB), Institute for Aging Research (IUIE), School of Medicine, Campus Mare Nostrum, University of Murcia, 30100, Murcia, Spain
| | - Víctor Bautista-Hernández
- Clinical & Experimental Neuroscience (NICE), Institute for Bio-Health Research of Murcia (IMIB), Institute for Aging Research (IUIE), School of Medicine, Campus Mare Nostrum, University of Murcia, 30100, Murcia, Spain.,Department of Cardiovascular Surgery, Complejo Hospitalario Universitario A Coruña (CHAUC), La Coruña, Spain
| | - Emiliano Fernández-Villalba
- Clinical & Experimental Neuroscience (NICE), Institute for Bio-Health Research of Murcia (IMIB), Institute for Aging Research (IUIE), School of Medicine, Campus Mare Nostrum, University of Murcia, 30100, Murcia, Spain
| | - María-Luisa Laorden
- Department of Pharmacology, School of Medicine, Campus Mare Nostrum, University of Murcia, Institute for Bio-Health Research of Murcia (IMIB), 30100, Murcia, Spain
| | - María-Trinidad Herrero
- Clinical & Experimental Neuroscience (NICE), Institute for Bio-Health Research of Murcia (IMIB), Institute for Aging Research (IUIE), School of Medicine, Campus Mare Nostrum, University of Murcia, 30100, Murcia, Spain.
| |
Collapse
|
8
|
Cuenca-Bermejo L, Pizzichini E, Gonçalves VC, Guillén-Díaz M, Aguilar-Moñino E, Sánchez-Rodrigo C, González-Cuello AM, Fernández-Villalba E, Herrero MT. A New Tool to Study Parkinsonism in the Context of Aging: MPTP Intoxication in a Natural Model of Multimorbidity. Int J Mol Sci 2021; 22:4341. [PMID: 33919373 PMCID: PMC8122583 DOI: 10.3390/ijms22094341] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2021] [Revised: 04/14/2021] [Accepted: 04/19/2021] [Indexed: 11/25/2022] Open
Abstract
The diurnal rodent Octodon degus (O. degus) is considered an attractive natural model for Alzheimer's disease and other human age-related features. However, it has not been explored so far if the O. degus could be used as a model to study Parkinson's disease. To test this idea, 10 adult male O. degus were divided into control group and MPTP-intoxicated animals. Motor condition and cognition were examined. Dopaminergic degeneration was studied in the ventral mesencephalon and in the striatum. Neuroinflammation was also evaluated in the ventral mesencephalon, in the striatum and in the dorsal hippocampus. MPTP animals showed significant alterations in motor activity and in visuospatial memory. Postmortem analysis revealed a significant decrease in the number of dopaminergic neurons in the ventral mesencephalon of MPTP animals, although no differences were found in their striatal terminals. We observed a significant increase in neuroinflammatory responses in the mesencephalon, in the striatum and in the hippocampus of MPTP-intoxicated animals. Additionally, changes in the subcellular expression of the calcium-binding protein S100β were found in the astrocytes in the nigrostriatal pathway. These findings prove for the first time that O. degus are sensitive to MPTP intoxication and, therefore, is a suitable model for experimental Parkinsonism in the context of aging.
Collapse
Affiliation(s)
- Lorena Cuenca-Bermejo
- Clinical and Experimental Neuroscience (NiCE), Institute for Aging Research (IUIE), School of Medicine, University of Murcia, 30100 Murcia, Spain; (L.C.-B.); (E.P.); (V.C.G.); (M.G.-D.); (E.A.-M.); (C.S.-R.); (A.-M.G.-C.)
- Biomedical Research Institute of Murcia (IMIB-Arrixaca), Campus Mare Nostrum, University of Murcia, 30120 Murcia, Spain
| | - Elisa Pizzichini
- Clinical and Experimental Neuroscience (NiCE), Institute for Aging Research (IUIE), School of Medicine, University of Murcia, 30100 Murcia, Spain; (L.C.-B.); (E.P.); (V.C.G.); (M.G.-D.); (E.A.-M.); (C.S.-R.); (A.-M.G.-C.)
- Department of Biology and Biotechnology “Charles Darwin” (BBCD), Sapienza, University of Rome, 00185 Rome, Italy
| | - Valeria C. Gonçalves
- Clinical and Experimental Neuroscience (NiCE), Institute for Aging Research (IUIE), School of Medicine, University of Murcia, 30100 Murcia, Spain; (L.C.-B.); (E.P.); (V.C.G.); (M.G.-D.); (E.A.-M.); (C.S.-R.); (A.-M.G.-C.)
- Disciplina de Neurociência, Departamento de Neurologia e Neurocirurgia, Universidade Federal de São Paulo (UNIFESP), São Paulo 04039-032, Brazil
| | - María Guillén-Díaz
- Clinical and Experimental Neuroscience (NiCE), Institute for Aging Research (IUIE), School of Medicine, University of Murcia, 30100 Murcia, Spain; (L.C.-B.); (E.P.); (V.C.G.); (M.G.-D.); (E.A.-M.); (C.S.-R.); (A.-M.G.-C.)
| | - Elena Aguilar-Moñino
- Clinical and Experimental Neuroscience (NiCE), Institute for Aging Research (IUIE), School of Medicine, University of Murcia, 30100 Murcia, Spain; (L.C.-B.); (E.P.); (V.C.G.); (M.G.-D.); (E.A.-M.); (C.S.-R.); (A.-M.G.-C.)
| | - Consuelo Sánchez-Rodrigo
- Clinical and Experimental Neuroscience (NiCE), Institute for Aging Research (IUIE), School of Medicine, University of Murcia, 30100 Murcia, Spain; (L.C.-B.); (E.P.); (V.C.G.); (M.G.-D.); (E.A.-M.); (C.S.-R.); (A.-M.G.-C.)
- Biomedical Research Institute of Murcia (IMIB-Arrixaca), Campus Mare Nostrum, University of Murcia, 30120 Murcia, Spain
| | - Ana-María González-Cuello
- Clinical and Experimental Neuroscience (NiCE), Institute for Aging Research (IUIE), School of Medicine, University of Murcia, 30100 Murcia, Spain; (L.C.-B.); (E.P.); (V.C.G.); (M.G.-D.); (E.A.-M.); (C.S.-R.); (A.-M.G.-C.)
- Biomedical Research Institute of Murcia (IMIB-Arrixaca), Campus Mare Nostrum, University of Murcia, 30120 Murcia, Spain
| | - Emiliano Fernández-Villalba
- Clinical and Experimental Neuroscience (NiCE), Institute for Aging Research (IUIE), School of Medicine, University of Murcia, 30100 Murcia, Spain; (L.C.-B.); (E.P.); (V.C.G.); (M.G.-D.); (E.A.-M.); (C.S.-R.); (A.-M.G.-C.)
- Biomedical Research Institute of Murcia (IMIB-Arrixaca), Campus Mare Nostrum, University of Murcia, 30120 Murcia, Spain
| | - María Trinidad Herrero
- Clinical and Experimental Neuroscience (NiCE), Institute for Aging Research (IUIE), School of Medicine, University of Murcia, 30100 Murcia, Spain; (L.C.-B.); (E.P.); (V.C.G.); (M.G.-D.); (E.A.-M.); (C.S.-R.); (A.-M.G.-C.)
- Biomedical Research Institute of Murcia (IMIB-Arrixaca), Campus Mare Nostrum, University of Murcia, 30120 Murcia, Spain
| |
Collapse
|
9
|
Navarro-Zaragoza J, Cuenca-Bermejo L, Almela P, Laorden ML, Herrero MT. Could Small Heat Shock Protein HSP27 Be a First-Line Target for Preventing Protein Aggregation in Parkinson's Disease? Int J Mol Sci 2021; 22:3038. [PMID: 33809767 PMCID: PMC8002365 DOI: 10.3390/ijms22063038] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2021] [Revised: 03/09/2021] [Accepted: 03/13/2021] [Indexed: 01/06/2023] Open
Abstract
Small heat shock proteins (HSPs), such as HSP27, are ubiquitously expressed molecular chaperones and are essential for cellular homeostasis. The major functions of HSP27 include chaperoning misfolded or unfolded polypeptides and protecting cells from toxic stress. Dysregulation of stress proteins is associated with many human diseases including neurodegenerative diseases, such as Parkinson's disease (PD). PD is characterized by the presence of aggregates of α-synuclein in the central and peripheral nervous system, which induces the degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and in the autonomic nervous system. Autonomic dysfunction is an important non-motor phenotype of PD, which includes cardiovascular dysregulation, among others. Nowadays, the therapies for PD focus on dopamine (DA) replacement. However, certain non-motor symptoms with a great impact on quality of life do not respond to dopaminergic drugs; therefore, the development and testing of new treatments for non-motor symptoms of PD remain a priority. Since small HSP27 was shown to prevent α-synuclein aggregation and cytotoxicity, this protein might constitute a suitable target to prevent or delay the motor and non-motor symptoms of PD. In the first part of our review, we focus on the cardiovascular dysregulation observed in PD patients. In the second part, we present data on the possible role of HSP27 in preventing the accumulation of amyloid fibrils and aggregated forms of α-synuclein. We also include our own studies, highlighting the possible protective cardiac effects induced by L-DOPA treatment through the enhancement of HSP27 levels and activity.
Collapse
Affiliation(s)
- Javier Navarro-Zaragoza
- Department of Pharmacology, School of Medicine, University of Murcia, Campus Mare Nostrum, 30100 Murcia, Spain; (J.N.-Z.); (M.-L.L.)
- Institute of Biomedical Research of Murcia (IMIB), Campus de Ciencias de la Salud, 30120 Murcia, Spain
| | - Lorena Cuenca-Bermejo
- Institute of Biomedical Research of Murcia (IMIB), Campus de Ciencias de la Salud, 30120 Murcia, Spain
- Clinical & Experimental Neuroscience (NICE), Institute for Aging Research, School of Medicine, University of Murcia, Campus Mare Nostrum, 30100 Murcia, Spain;
| | - Pilar Almela
- Department of Pharmacology, School of Medicine, University of Murcia, Campus Mare Nostrum, 30100 Murcia, Spain; (J.N.-Z.); (M.-L.L.)
- Institute of Biomedical Research of Murcia (IMIB), Campus de Ciencias de la Salud, 30120 Murcia, Spain
| | - María-Luisa Laorden
- Department of Pharmacology, School of Medicine, University of Murcia, Campus Mare Nostrum, 30100 Murcia, Spain; (J.N.-Z.); (M.-L.L.)
- Institute of Biomedical Research of Murcia (IMIB), Campus de Ciencias de la Salud, 30120 Murcia, Spain
| | - María-Trinidad Herrero
- Institute of Biomedical Research of Murcia (IMIB), Campus de Ciencias de la Salud, 30120 Murcia, Spain
- Clinical & Experimental Neuroscience (NICE), Institute for Aging Research, School of Medicine, University of Murcia, Campus Mare Nostrum, 30100 Murcia, Spain;
| |
Collapse
|
10
|
Gonçalves VC, Cuenca-Bermejo L, Fernandez-Villalba E, Martin-Balbuena S, da Silva Fernandes MJ, Scorza CA, Herrero MT. Heart Matters: Cardiac Dysfunction and Other Autonomic Changes in Parkinson's Disease. Neuroscientist 2021; 28:530-542. [PMID: 33583239 DOI: 10.1177/1073858421990000] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
It has been more than 200 years since James Parkinson made the first descriptions of the disease that bears his name. Since then, knowledge about Parkinson's disease has been improved, and its pathophysiology, diagnosis, and treatments are well described in the scientific and medical literature. However, there is no way to prevent the disease from its progressive nature yet and only its symptoms can be minimized. It is known that the process of neurodegeneration begins before the onset of motor signs and symptoms of the disease, when diagnosis is usually made. Therefore, recognizing manifested non-motor symptoms can make an early diagnosis possible and lead to a better understanding of the disease. Autonomic dysfunctions are important non-motor manifestations of Parkinson's disease and affect the majority of patients. Importantly, heart failure is the third leading cause of death in people suffering from Parkinson's disease. Several evidences have shown the correlation between Parkinson's disease and the preexistence of cardiovascular diseases. Therefore, cardiovascular monitoring and identification of its dysfunctions can have a prodromal role for Parkinson's disease. This review presents studies of the literature that can lead to a better understanding of Parkinson's disease with special attention to its relation to heart and cardiovascular parameters.
Collapse
Affiliation(s)
- Valeria C Gonçalves
- Clinical & Experimental Neuroscience (NiCE), Biomedical Research Institute of Murcia (IMIB- Arrixaca), Murcia, Spain.,Clinical & Experimental Neuroscience (NiCE), Institute for Ageing Research (IUIE), School of Medicine, Campus Mare Nostrum. University of Murcia, Murcia, Spain.,Disciplina de Neurociência, Departamento de Neurologia e Neurocirurgia, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil
| | - Lorena Cuenca-Bermejo
- Clinical & Experimental Neuroscience (NiCE), Biomedical Research Institute of Murcia (IMIB- Arrixaca), Murcia, Spain.,Clinical & Experimental Neuroscience (NiCE), Institute for Ageing Research (IUIE), School of Medicine, Campus Mare Nostrum. University of Murcia, Murcia, Spain
| | - Emiliano Fernandez-Villalba
- Clinical & Experimental Neuroscience (NiCE), Biomedical Research Institute of Murcia (IMIB- Arrixaca), Murcia, Spain.,Clinical & Experimental Neuroscience (NiCE), Institute for Ageing Research (IUIE), School of Medicine, Campus Mare Nostrum. University of Murcia, Murcia, Spain
| | - Sebastian Martin-Balbuena
- Clinical & Experimental Neuroscience (NiCE), Biomedical Research Institute of Murcia (IMIB- Arrixaca), Murcia, Spain.,Clinical & Experimental Neuroscience (NiCE), Institute for Ageing Research (IUIE), School of Medicine, Campus Mare Nostrum. University of Murcia, Murcia, Spain
| | - Maria Jose da Silva Fernandes
- Disciplina de Neurociência, Departamento de Neurologia e Neurocirurgia, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil
| | - Carla A Scorza
- Disciplina de Neurociência, Departamento de Neurologia e Neurocirurgia, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil
| | - Maria-Trinidad Herrero
- Clinical & Experimental Neuroscience (NiCE), Biomedical Research Institute of Murcia (IMIB- Arrixaca), Murcia, Spain.,Clinical & Experimental Neuroscience (NiCE), Institute for Ageing Research (IUIE), School of Medicine, Campus Mare Nostrum. University of Murcia, Murcia, Spain
| |
Collapse
|
11
|
Gil-Martinez AL, Cuenca-Bermejo L, Gallo-Soljancic P, Sanchez-Rodrigo C, Izura V, Steinbusch HWM, Fernandez-Villalba E, Herrero MT. Study of the Link Between Neuronal Death, Glial Response, and MAPK Pathway in Old Parkinsonian Mice. Front Aging Neurosci 2020; 12:214. [PMID: 32848701 PMCID: PMC7403503 DOI: 10.3389/fnagi.2020.00214] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2020] [Accepted: 06/18/2020] [Indexed: 12/16/2022] Open
Abstract
Background: Parkinson’s disease (PD) is described as an age-related neurodegenerative disorder. However, the vast majority of research is carried out using experimental models of young animals lacking the implications of the decline processes associated with aging. It has been suggested that several molecular pathways are involved in the perpetuation of the degeneration and the neuroinflammation in PD. Among others, mitogen-activated protein kinases (MAPKs) have been highly implicated in the development of PD, and regulating components of their activity are indicated as promising therapeutic targets. Methods: To further define how MAPKs expression is related to the glial response and neuronal cell death, Parkinsonism was induced under an acute regimen in old mice. Moreover, the sacrifice was carried out at different time points (4, 8, 24, and 48 h) after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP) injections to describe the early dynamic changes over time produced by the intoxication. Results: The results revealed that neuronal death increases as glial response increases in the nigrostriatal pathway. It was observed that both processes increase from 4 h in the ventral mesencephalon (VM), and neuronal death becomes significant at 48 h. In the striatum, they were significantly increased from 48 h after the MPTP administration compared with that in the control mice. Moreover, the p-ERK levels decrease, while phospho-p38 expression increases specifically in the striatum at 48 h after MPTP intoxication. Conclusions: The importance of these data lies in the possibility of elucidating the underlying mechanisms of neurodegenerative processes under aging conditions to provide knowledge for the search of solutions that slow down the progression of PD.
Collapse
Affiliation(s)
- Ana Luisa Gil-Martinez
- Clinical and Experimental Neuroscience Group (NiCE), Institute for Aging Research, School of Medicine, Regional Campus of International Excellence "Campus Mare Nostrum", University of Murcia, Murcia, Spain.,Biomedical Research Institute of Murcia (IMIB-Arrixaca), University of Murcia, Murcia, Spain.,School for Mental Health and Neuroscience (MHeNs), Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, Netherlands
| | - Lorena Cuenca-Bermejo
- Clinical and Experimental Neuroscience Group (NiCE), Institute for Aging Research, School of Medicine, Regional Campus of International Excellence "Campus Mare Nostrum", University of Murcia, Murcia, Spain.,Biomedical Research Institute of Murcia (IMIB-Arrixaca), University of Murcia, Murcia, Spain
| | - Pablo Gallo-Soljancic
- Clinical and Experimental Neuroscience Group (NiCE), Institute for Aging Research, School of Medicine, Regional Campus of International Excellence "Campus Mare Nostrum", University of Murcia, Murcia, Spain.,Biomedical Research Institute of Murcia (IMIB-Arrixaca), University of Murcia, Murcia, Spain
| | - Consuelo Sanchez-Rodrigo
- Clinical and Experimental Neuroscience Group (NiCE), Institute for Aging Research, School of Medicine, Regional Campus of International Excellence "Campus Mare Nostrum", University of Murcia, Murcia, Spain.,Biomedical Research Institute of Murcia (IMIB-Arrixaca), University of Murcia, Murcia, Spain
| | - Virginia Izura
- Clinical and Experimental Neuroscience Group (NiCE), Institute for Aging Research, School of Medicine, Regional Campus of International Excellence "Campus Mare Nostrum", University of Murcia, Murcia, Spain.,Biomedical Research Institute of Murcia (IMIB-Arrixaca), University of Murcia, Murcia, Spain
| | - Harry W M Steinbusch
- School for Mental Health and Neuroscience (MHeNs), Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, Netherlands
| | - Emiliano Fernandez-Villalba
- Clinical and Experimental Neuroscience Group (NiCE), Institute for Aging Research, School of Medicine, Regional Campus of International Excellence "Campus Mare Nostrum", University of Murcia, Murcia, Spain.,Biomedical Research Institute of Murcia (IMIB-Arrixaca), University of Murcia, Murcia, Spain
| | - Maria Trinidad Herrero
- Clinical and Experimental Neuroscience Group (NiCE), Institute for Aging Research, School of Medicine, Regional Campus of International Excellence "Campus Mare Nostrum", University of Murcia, Murcia, Spain.,Biomedical Research Institute of Murcia (IMIB-Arrixaca), University of Murcia, Murcia, Spain
| |
Collapse
|
12
|
Almela P, Cuenca-Bermejo L, Yuste JE, Estrada C, de Pablos V, Bautista-Hernández V, Fernández-Villalba E, Laorden ML, Herrero MT. Cardiac Noradrenaline Turnover and Heat Shock Protein 27 Phosphorylation in Dyskinetic Monkeys. Mov Disord 2019; 35:698-703. [PMID: 31872915 DOI: 10.1002/mds.27958] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2019] [Revised: 11/25/2019] [Accepted: 11/26/2019] [Indexed: 11/08/2022] Open
Abstract
BACKGROUND Autonomic dysfunction is a well-known dominant symptom in the advanced stages of Parkinson's disease. However, the role of cardiac sympathetic nerves still needs to be elucidated. OBJECTIVES To evaluate cardiac sympathetic response in Parkinsonian and dyskinetic monkeys. METHODS Adult male monkeys were divided into 1 of the following 3 groups: controls, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine+levodopa-treated animals. Noradrenaline, its metabolite normetanephrine, and phospho-Heat shock proten 27 (p-Hsp27) at serine 82 levels were analyzed in the left and right ventricles of the heart. Tyrosine hydroxylase immunohistochemistry was performed in the ventral mesencephalon. RESULTS The results were the following: (1) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication significantly increased normetanephrine levels and decreased noradrenaline turnover in the right ventricle without changes in the left ventricle; however, (2) levodopa treatment decreased noradrenaline levels and enhanced the normetanephrine/noradrenaline ratio in parallel with a very significant increase of Hsp27 activity in both ventricles. CONCLUSIONS Levodopa treatment could induce protective cardiac effects through the increased Hsp27 activity. © 2019 International Parkinson and Movement Disorder Society.
Collapse
Affiliation(s)
- Pilar Almela
- Department of Pharmacology, School of Medicine, University of Murcia, Murcia, Spain.,Institute of Biomedical Research of Murcia (IMIB), Campus de Ciencias de la Salud, Carretera Buenavista s/n, 30120 El Palmar, Murcia, España
| | - Lorena Cuenca-Bermejo
- Institute of Biomedical Research of Murcia (IMIB), Campus de Ciencias de la Salud, Carretera Buenavista s/n, 30120 El Palmar, Murcia, España.,Clinical & Experimental Neuroscience, Institute for Aging Research, School of Medicine, University of Murcia, Murcia, Spain
| | - José E Yuste
- Clinical & Experimental Neuroscience, Institute for Aging Research, School of Medicine, University of Murcia, Murcia, Spain
| | - Cristina Estrada
- Institute of Biomedical Research of Murcia (IMIB), Campus de Ciencias de la Salud, Carretera Buenavista s/n, 30120 El Palmar, Murcia, España.,Clinical & Experimental Neuroscience, Institute for Aging Research, School of Medicine, University of Murcia, Murcia, Spain
| | - Vicente de Pablos
- Institute of Biomedical Research of Murcia (IMIB), Campus de Ciencias de la Salud, Carretera Buenavista s/n, 30120 El Palmar, Murcia, España.,Clinical & Experimental Neuroscience, Institute for Aging Research, School of Medicine, University of Murcia, Murcia, Spain
| | - Víctor Bautista-Hernández
- Clinical & Experimental Neuroscience, Institute for Aging Research, School of Medicine, University of Murcia, Murcia, Spain.,Department of Cardiovascular Surgery, Integrated Management Area of A Coruña, La Coruña, Spain
| | - Emiliano Fernández-Villalba
- Institute of Biomedical Research of Murcia (IMIB), Campus de Ciencias de la Salud, Carretera Buenavista s/n, 30120 El Palmar, Murcia, España.,Clinical & Experimental Neuroscience, Institute for Aging Research, School of Medicine, University of Murcia, Murcia, Spain
| | - María-Luisa Laorden
- Department of Pharmacology, School of Medicine, University of Murcia, Murcia, Spain.,Clinical & Experimental Neuroscience, Institute for Aging Research, School of Medicine, University of Murcia, Murcia, Spain
| | - María-Trinidad Herrero
- Institute of Biomedical Research of Murcia (IMIB), Campus de Ciencias de la Salud, Carretera Buenavista s/n, 30120 El Palmar, Murcia, España.,Clinical & Experimental Neuroscience, Institute for Aging Research, School of Medicine, University of Murcia, Murcia, Spain
| |
Collapse
|